Bone Biologics Corp — Form 8-K
Filed July 9, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On July 9, 2026, Bone Biologics Corporation issued Series F and Series G Common Stock Purchase Warrants (exercise price $1.42, 5-year and 18-month terms respectively), Pre-Funded Warrants (exercise price $0.001), and Placement Agent Warrants (exercise price $1.775) to accredited investors under a Securities Purchase Agreement dated July 7, 2026. The filing does not specify dollar amounts or share counts. H.C. Wainwright Co., LLC served as placement agent. This is a standard equity financing by a micro-cap company.
Why this rating
Warrant and equity issuance is routine for small biotechs. No dollar amount or share count disclosed makes impact assessment difficult. Boilerplate transaction documents.
See more from July 9, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.